| Q26765155 | A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus |
| Q52575496 | A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs. |
| Q47736265 | A Vitamin B12 Conjugate of Exendin-4 Improves Glucose Tolerance Without Associated Nausea or Hypophagia in Rodents. |
| Q26799389 | A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond |
| Q38020941 | A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes |
| Q51483637 | A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. |
| Q27027240 | A continued saga of Boc5, the first non-peptidic glucagon-like peptide-1 receptor agonist with in vivo activities |
| Q41623756 | A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus |
| Q45749290 | A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment |
| Q37568754 | A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease |
| Q38041660 | A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. |
| Q52667455 | A novel peptide Phylloseptin-PBu from Phyllomedusa burmeisteri possesses insulinotropic activity via potassium channel and GLP-1 receptor signalling. |
| Q42846868 | A placebo‐controlled trial of exenatide twice‐daily added to thiazolidinediones alone or in combination with metformin |
| Q37403218 | A review of exenatide as adjunctive therapy in patients with type 2 diabetes |
| Q36428082 | A review of exenatide: optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes |
| Q38282880 | A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy |
| Q38035684 | A therapeutic approach to hyperglycaemia in the setting of acute myocardial infarction: spotlight on glucagon-like peptide 1. |
| Q37818234 | Add-on therapies to metformin for type 2 diabetes |
| Q45985239 | Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. |
| Q51424631 | Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes. |
| Q36546914 | Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy |
| Q43086326 | Addition of incretin therapy to metformin in type 2 diabetes |
| Q46030058 | Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis. |
| Q42673250 | Adipocyte expression of the glucose-dependent insulinotropic polypeptide receptor involves gene regulation by PPARγ and histone acetylation |
| Q37960391 | Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus. |
| Q38072616 | Advances in pharmacologic therapies for type 2 diabetes |
| Q26784022 | Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum |
| Q26801346 | Adverse Effects of GLP-1 Receptor Agonists |
| Q37724230 | Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes |
| Q37131132 | Allosteric modulators of class B G-protein-coupled receptors |
| Q34620671 | Alogliptin: a new addition to the class of DPP-4 inhibitors |
| Q36758533 | Alterations in energy balance following exenatide administration |
| Q37427453 | An intrinsic agonist mechanism for activation of glucagon-like peptide-1 receptor by its extracellular domain. |
| Q91697051 | An overview of GLP-1 agonists and recent cardiovascular outcomes trials |
| Q37688031 | Antidiabetic oral treatment in older people: does frailty matter? |
| Q46988910 | Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures |
| Q38219485 | Application of clinical judgment and guidelines to achieving glycemic goals in type 2 diabetes: focus on pharmacologic therapy |
| Q50801252 | Approaches to help people with diabetes overcome barriers for improved health outcomes. |
| Q26829445 | Assessment of pancreatic β-cell function: review of methods and clinical applications |
| Q34618507 | Association of pancreatitis with glucagon-like peptide-1 agonist use. |
| Q26827955 | Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes |
| Q37141727 | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus |
| Q51744991 | Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption. |
| Q37677036 | Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus |
| Q51322701 | Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. |
| Q35951495 | Beta cell transplantation and immunosuppression: can't live with it, can't live without it. |
| Q46558640 | Beyond glycemic control: the effects of incretin hormones in type 2 diabetes |
| Q37612693 | Beyond glycemic control: treating the entire type 2 diabetes disorder |
| Q37199333 | Beyond insulin replacement: addressing the additional needs of the diabetes patient |
| Q37961847 | Beyond metformin: initiating combination therapy in patients with type 2 diabetes mellitus |
| Q37517909 | Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum |
| Q36267715 | Bioactivity of a modified human Glucagon-like peptide-1. |
| Q36575421 | Biologic actions and therapeutic potential of the proglucagon-derived peptides |
| Q34717929 | Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus |
| Q37508420 | Bowels control brain: gut hormones and obesity |
| Q49027654 | Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4. |
| Q40815972 | Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans |
| Q37767398 | Can therapies that target the incretin system improve our ability to treat type 2 diabetes? |
| Q35936644 | Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control |
| Q26741082 | Cardiovascular safety of anti-diabetic drugs |
| Q28741419 | Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes |
| Q38960547 | Cardiovascular safety of therapies for type 2 diabetes |
| Q46482950 | Case study 2: new insights: clinical pearls for using incretin mimetics in type 2 diabetes |
| Q36428808 | Challenges and strategies for moving patients to injectable medications |
| Q34567005 | Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes |
| Q36489155 | Characterization of Patients with Type 2 Diabetes according to Body Mass Index: Korea National Health and Nutrition Examination Survey from 2007 to 2011. |
| Q36510864 | Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding |
| Q40946879 | Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach |
| Q48799668 | Choosing targets for glycaemia, blood pressure and low-density lipoprotein cholesterol in elderly individuals with diabetes mellitus |
| Q34978556 | Chronic elevation of systemic glucagon-like peptide-1 following surgical weight loss: association with nausea and vomiting and effects on adipokines |
| Q37410215 | Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus |
| Q37979850 | Clinical considerations for the management of residual diabetes following bariatric surgery |
| Q46760415 | Clinical experience with exenatide in predominantly Asian and Pacific Islander patients with type 2 diabetes |
| Q38267138 | Clinical pharmacology of albiglutide, a GLP-1 receptor agonist |
| Q37641329 | Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus |
| Q46381359 | Combination pharmacotherapy with incretins: what works best and when? |
| Q33609727 | Combination treatment of db/db mice with exendin-4 and gastrin preserves β-cell mass by stimulating β-cell growth and differentiation. |
| Q33664063 | Combinations of drugs in the Treatment of Obesity |
| Q27004723 | Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes |
| Q36835841 | Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease |
| Q80035754 | Comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetolo |
| Q36511814 | Common crossroads in diabetes management |
| Q36354602 | Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials |
| Q37659673 | Comparative effectiveness of liraglutide in the treatment of type 2 diabetes |
| Q28546797 | Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis |
| Q36783891 | Comparative efficiency and safety of pharmacological approaches to the management of obesity |
| Q38213037 | Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure |
| Q36073461 | Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists |
| Q36725186 | Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial |
| Q37992255 | Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents |
| Q38116766 | Complementing insulin therapy to achieve glycemic control |
| Q38167147 | Complications of diabetes therapy. |
| Q43042719 | Contemporary management of patients with Type 2 diabetes |
| Q41288731 | Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin |
| Q50230933 | Cost-effectiveness of a risk-based secondary screening programme of type 2 diabetes. |
| Q42867343 | Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications |
| Q34620447 | Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus |
| Q64066052 | Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes |
| Q37860396 | Current and emerging antiglycaemic pharmacological therapies: the renal perspective |
| Q34344786 | Current and investigational antiobesity agents and obesity therapeutic treatment targets |
| Q41832154 | Current and novel therapies for the treatment of nonalcoholic steatohepatitis |
| Q38005223 | Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists? |
| Q37221785 | DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients? |
| Q40718093 | DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks |
| Q35061423 | Determining predictors of early response to exenatide in patients with type 2 diabetes mellitus |
| Q33949425 | Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies |
| Q34716791 | Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies |
| Q37524006 | Diabetes medications and body weight |
| Q37554194 | Diabetes mellitus and gastric emptying: questions and issues in clinical practice |
| Q34829290 | Diabetes: glycaemic control in type 2 (drug treatments). |
| Q90079464 | Dietary Intake and Type 2 Diabetes |
| Q38198185 | Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis |
| Q48282439 | Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes |
| Q38597109 | Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy |
| Q41863397 | Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus |
| Q34524274 | Differentiation of human adipose-derived mesenchymal stem cell into insulin-producing cells: an in vitro study. |
| Q37022837 | Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes |
| Q37035092 | Dipeptidyl peptidase-iV inhibitors: fixing type 2 diabetes? |
| Q45742352 | Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation? |
| Q80160244 | Does exenatide provide a meaningful new treatment option for patients with type 2 diabetes? |
| Q43180130 | Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide |
| Q34745045 | Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial |
| Q38003273 | Drug-drug interactions with glucagon-like peptide-1 receptor agonists |
| Q24197984 | Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis |
| Q24246447 | Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis |
| Q36269675 | Drugs on the horizon for diabesity. |
| Q26861768 | Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes |
| Q45986635 | Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism. |
| Q85305515 | Early therapy for type 2 diabetes in China |
| Q38001085 | Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. |
| Q90298191 | Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug-naïve type 2 diabetic patients |
| Q48329014 | Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial |
| Q53588433 | Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. |
| Q34201503 | Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial |
| Q36024667 | Effect of renal impairment on the pharmacokinetics of exenatide |
| Q45868438 | Effective and safe gene-based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes |
| Q28067209 | Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients |
| Q42633689 | Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice |
| Q27011627 | Effects of GLP-1 on appetite and weight |
| Q36584204 | Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. |
| Q46869132 | Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy |
| Q42101166 | Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes |
| Q44620317 | Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes |
| Q44199179 | Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome |
| Q47769217 | Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials |
| Q35996636 | Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis |
| Q37951097 | Effects of incretins on blood pressure: a promising therapy for type 2 diabetes mellitus with hypertension |
| Q36011993 | Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis |
| Q34598940 | Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study |
| Q28286240 | Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial |
| Q33603466 | Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus |
| Q37193446 | Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). |
| Q51332907 | Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). |
| Q37106572 | Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). |
| Q37897817 | Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis |
| Q90066171 | Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial |
| Q38908205 | Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials |
| Q36249636 | Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial |
| Q36428087 | Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). |
| Q51489068 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. |
| Q38285665 | Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspective |
| Q28088578 | Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus |
| Q60209721 | Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study |
| Q46885175 | Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study |
| Q37929744 | Emerging GLP-1 receptor agonists |
| Q37395298 | Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? |
| Q34207458 | Emerging pharmacotherapy for obesity |
| Q34620465 | Emerging role of GLP-1 receptor agonists in the treatment of obesity |
| Q34381281 | Emerging treatment options for type 2 diabetes |
| Q37971089 | Encapsulated cell grafts to treat cellular deficiencies and dysfunction |
| Q28196750 | Evaluating and treating cardiometabolic risk factors: a case discussion |
| Q38095231 | Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors |
| Q39190208 | Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates. |
| Q33931988 | Evaluation and management of diabetes mellitus |
| Q36897192 | Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom |
| Q38219482 | Evidence-based practice use of incretin-based therapy in the natural history of diabetes |
| Q36877205 | Evolution of exenatide as a diabetes therapeutic |
| Q80974729 | Exenatide |
| Q81247842 | Exenatide |
| Q82582041 | Exenatide |
| Q24548814 | Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus |
| Q89208137 | Exenatide Effects on Cardiometabolic Risk and Weight in Adolescents with Morbid Obesity and Type 2 Diabetes Mellitus: Two Case Reports |
| Q36656331 | Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women. |
| Q33664114 | Exenatide Use in the Management of Type 2 Diabetes Mellitus |
| Q37049686 | Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity |
| Q30540208 | Exenatide and the treatment of patients with Parkinson's disease |
| Q37119264 | Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction |
| Q42683864 | Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin |
| Q36538817 | Exenatide extended-release; clinical trials, patient preference, and economic considerations |
| Q51732619 | Exenatide has a Pronounced Effect on Energy Intake but not Energy Expenditure in Non-Diabetic Subjects with Obesity: A Randomized, Double-blind, Placebo-Controlled Trial. |
| Q43678308 | Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research |
| Q42660412 | Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes |
| Q33884913 | Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years |
| Q59624425 | Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study |
| Q28293505 | Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study |
| Q34144380 | Exenatide once weekly: clinical outcomes and patient satisfaction. |
| Q42091988 | Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years |
| Q51357618 | Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes. |
| Q47567913 | Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus |
| Q38179267 | Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus |
| Q30558739 | Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index |
| Q35183579 | Exenatide's effect in reducing weight and glycosylated hemoglobin level in an Arab population with type 2 diabetes |
| Q34530205 | Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus |
| Q36598110 | Exenatide: a new option for the treatment of type 2 diabetes |
| Q34618193 | Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). |
| Q38770746 | Exenatide: pharmacokinetics, clinical use, and future directions |
| Q58567055 | Exendin-4 Overcomes Cytokine-Induced Decreases in Gap Junction Coupling via PKA and Epac2 in Mouse and Human Islets |
| Q42045527 | Exendin-4 does not promote Beta-cell proliferation or survival during the early post-islet transplant period in mice |
| Q36306579 | Exendin-4 improves resistance to Listeria monocytogenes infection in diabetic db/db mice |
| Q35563969 | Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets. |
| Q35943572 | Exendin-4 protects bone marrow-derived mesenchymal stem cells against oxygen/glucose and serum deprivation-induced apoptosis through the activation of the cAMP/PKA signaling pathway and the attenuation of ER stress |
| Q35034582 | Exendin-4 protects mitochondria from reactive oxygen species induced apoptosis in pancreatic Beta cells |
| Q58448396 | Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats |
| Q46121472 | Expanding treatment options for type 2 diabetes: the old and the new. |
| Q34745109 | Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. |
| Q38194069 | Extra-pancreatic effects of incretin-based therapies |
| Q38065321 | Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes |
| Q37835612 | Focus on incretin-based therapies: targeting the core defects of type 2 diabetes |
| Q37900151 | From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy |
| Q34187972 | GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene |
| Q64888050 | GLP-1 Limits Adipocyte Inflammation and Its Low Circulating Pre-Operative Concentrations Predict Worse Type 2 Diabetes Remission after Bariatric Surgery in Obese Patients. |
| Q55051694 | GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes. |
| Q38602769 | GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice |
| Q37885717 | GLP-1 and energy balance: an integrated model of short-term and long-term control |
| Q35200252 | GLP-1 based therapeutics: simultaneously combating T2DM and obesity. |
| Q37974712 | GLP-1 based therapies: differential effects on fasting and postprandial glucose |
| Q26858990 | GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence |
| Q39961713 | GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1. |
| Q38040314 | GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus |
| Q38002008 | GLP-1 receptor agonists: a clinical perspective on cardiovascular effects |
| Q33753096 | GLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-dependent HIF-1α activation |
| Q37049674 | GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors |
| Q43116132 | GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus |
| Q38207948 | GLP-1R activation for the treatment of stroke: updating and future perspectives |
| Q37404603 | Gastric electrical stimulation with the TANTALUS System in obese type 2 diabetes patients: effect on weight and glycemic control |
| Q38208929 | Gastrointestinal hormones and polycystic ovary syndrome |
| Q37047199 | Gastrointestinal peptides controlling body weight homeostasis. |
| Q79676350 | Gliptins |
| Q46919674 | Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans |
| Q47174979 | Glucagon-like peptide 1 and pancreatic polypeptide responses to feeding in normal weight and overweight children |
| Q37134320 | Glucagon-like peptide 1 based therapy for type 2 diabetes |
| Q38243035 | Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective |
| Q24243685 | Glucagon-like peptide analogues for type 2 diabetes mellitus |
| Q33767049 | Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis |
| Q37929159 | Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents |
| Q37015969 | Glucagon-like peptide-1 analogues: An overview |
| Q38690867 | Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. |
| Q41983958 | Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials |
| Q28070416 | Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome |
| Q26752699 | Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future |
| Q91198085 | Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? |
| Q37825946 | Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. |
| Q36369954 | Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. |
| Q37921903 | Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy? |
| Q36816194 | Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes. |
| Q37598258 | Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors |
| Q34265490 | Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis |
| Q39988607 | Glycemic control impact on body weight potential to reduce cardiovascular risk: glucagon-like peptide 1 agonists |
| Q92106443 | Gut Peptide Agonism in the Treatment of Obesity and Diabetes |
| Q28278826 | Gut hormones and the regulation of energy homeostasis |
| Q37057996 | Gut hormones as potential new targets for appetite regulation and the treatment of obesity |
| Q40368897 | Hindbrain GLP-1 receptor mediation of cisplatin-induced anorexia and nausea |
| Q36640585 | How do different GLP-1 mimetics differ in their actions? |
| Q42171217 | How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation |
| Q34739954 | Hypoglycaemia in Type 2 diabetes |
| Q33739048 | Hypoglycemia: a review of definitions used in clinical trials evaluating antihyperglycemic drugs for diabetes |
| Q35972348 | Hypothalamic obesity in patients with craniopharyngioma: profound changes of several weight regulatory circuits |
| Q36520655 | Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis |
| Q48336084 | Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database. |
| Q38524435 | Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes |
| Q46140543 | Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes |
| Q26862823 | Impact of postprandial glycaemia on health and prevention of disease |
| Q37071750 | Impact of therapeutic advances on hypoglycaemia in type 2 diabetes |
| Q38264374 | Implications of incretin-based therapies on cardiovascular disease. |
| Q37396692 | Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2rγ(null) mice treated with alogliptin |
| Q35027845 | Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids. |
| Q33585633 | Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks |
| Q37794288 | In support of an early polypharmacy approach to the treatment of type 2 diabetes |
| Q34374336 | Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors |
| Q37653125 | Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes |
| Q37772709 | Incretin agents in type 2 diabetes. |
| Q26827183 | Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease |
| Q37921901 | Incretin effect: GLP-1, GIP, DPP4. |
| Q39988564 | Incretin effects on β-cell function, replication, and mass: the human perspective |
| Q38072203 | Incretin hormones and the satiation signal. |
| Q37280699 | Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes |
| Q36407215 | Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus |
| Q37198836 | Incretin mimetics and enhancers for the treatment of type 2 diabetes mellitus |
| Q34620479 | Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review |
| Q37858364 | Incretin therapies in the management of elderly patients with type 2 diabetes mellitus |
| Q35760283 | Incretin therapy--present and future |
| Q51456897 | Incretin-based Therapies for Type 2 Diabetes. |
| Q37894864 | Incretin-based therapies |
| Q37483473 | Incretin-based therapies for type 2 diabetes mellitus |
| Q37760515 | Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects |
| Q42748385 | Incretin-based therapies for type 2 diabetes: a nurse's perspective |
| Q36786998 | Incretin-based therapies for type 2 diabetes: clinical utility |
| Q36964866 | Incretin-based therapies in type 2 diabetes mellitus |
| Q38140803 | Incretin-based therapies: focus on effects beyond glycemic control alone |
| Q37316259 | Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. |
| Q37780914 | Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge |
| Q42578569 | Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus |
| Q36945112 | Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors |
| Q35690970 | Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose |
| Q37082698 | Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering |
| Q34374350 | Incretins: Clinical Perspectives, Relevance, and Applications for the Primary Care Physician in the Treatment of Patients With Type 2 Diabetes Mellitus |
| Q42627337 | Incretins: clinical physiology and bariatric surgery--correlating the entero-endocrine system and a potentially anti-dysmetabolic procedure |
| Q38225693 | Incretins: their physiology and application in the treatment of diabetes mellitus. |
| Q34225924 | Initial evidence that GLP-1 receptor blockade fails to suppress postprandial satiety or promote food intake in humans |
| Q38805958 | Input Estimation for Extended-Release Formulations Exemplified with Exenatide |
| Q37505840 | Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies |
| Q38008005 | Insulin initiation in type 2 diabetes: what are the treatment regimen options and how can we best help patients feel empowered? |
| Q36966075 | Insulin-associated weight gain in diabetes--causes, effects and coping strategies |
| Q39157526 | Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit? |
| Q51168180 | Intravail: highly effective intranasal delivery of peptide and protein drugs. |
| Q36268360 | Investigational agents that protect pancreatic islet beta-cells from failure |
| Q30426407 | Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? |
| Q36349625 | Is exenatide advancing the treatment of type 2 diabetes? |
| Q37845218 | Is the GLP-1 system a viable therapeutic target for weight reduction? |
| Q37443837 | Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes |
| Q55069710 | Japanese Clinical Practice Guideline for Diabetes 2016. |
| Q34090860 | Ketoconazole enantiomer for the treatment of diabetes mellitus |
| Q33785308 | Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. |
| Q30924982 | Liraglutide and obesity: a review of the data so far. |
| Q38536672 | Liraglutide for Type 2 diabetes and obesity: a 2015 update |
| Q37874613 | Liraglutide for type 2 diabetes mellitus |
| Q34986024 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). |
| Q46344895 | Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial |
| Q43086322 | Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial |
| Q37778209 | Liraglutide: A once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus |
| Q37933408 | Liraglutide: clinical pharmacology and considerations for therapy |
| Q37795877 | Liraglutide: effects beyond glycaemic control in diabetes treatment |
| Q64075913 | Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output |
| Q51317065 | Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials. |
| Q34180791 | Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability |
| Q43225003 | Long-term metabolic and hormonal effects of exenatide on islet transplant recipients with allograft dysfunction |
| Q33585566 | Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes |
| Q38216039 | Long-term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: a retrospective study from a specialist diabetes outpatient clinic |
| Q42977464 | Longacting exenatide in diabetes: DURATION-3. |
| Q57406244 | Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature |
| Q36613938 | Management of Type 2 diabetes: the role of incretin mimetics |
| Q36519973 | Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. |
| Q38020015 | Managing diabetes from first diagnosis: choosing well-tolerated therapies with durability |
| Q41945986 | Mechanism of metabolic advantages after bariatric surgery: it's all gastrointestinal factors versus it's all food restriction. |
| Q24683764 | Mechanisms of action of glucagon-like peptide 1 in the pancreas |
| Q37125932 | Mechanisms of disease: the role of gastrointestinal hormones in appetite and obesity. |
| Q34862358 | Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes |
| Q24642503 | Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes |
| Q34782893 | Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study |
| Q36309632 | Medications associated with weight gain |
| Q36012896 | Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes |
| Q37922651 | Metabolic surgery-principles and current concepts |
| Q37316440 | Metabolic vs. hedonic obesity: a conceptual distinction and its clinical implications |
| Q22241787 | Metformin -- life begins at 50: A symposium held on the occasion of the 43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam, The Netherlands, September 2007 |
| Q37386201 | Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release |
| Q37262966 | Metformin therapy and clinical uses |
| Q47108056 | Microneedle-array patches loaded with dual mineralized protein/peptide particles for type 2 diabetes therapy. |
| Q37210769 | Minireview: Gut peptides: targets for antiobesity drug development? |
| Q38190197 | Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus |
| Q33590792 | Molecular modeling of lanthionine synthetase component C-like protein 2: a potential target for the discovery of novel type 2 diabetes prophylactics and therapeutics |
| Q37183979 | More choices than ever before: emerging therapies for type 2 diabetes |
| Q37828337 | Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies |
| Q58591916 | Multivalent activation of GLP-1 and Sulfonylurea receptors modulates β-cell Second Messenger Signaling and Insulin Secretion |
| Q34592864 | Neonatal exendin-4 reduces growth, fat deposition and glucose tolerance during treatment in the intrauterine growth-restricted lamb |
| Q38937626 | New Approaches to Feline Diabetes Mellitus: Glucagon-like peptide-1 analogs. |
| Q36459419 | New and emerging strategies for reducing cardiometabolic risk factors |
| Q37306767 | New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. |
| Q37886661 | New drug targets for the treatment of obesity. |
| Q37288741 | New drugs for type 2 diabetes mellitus: what is their place in therapy? |
| Q46710458 | New oral antidiabetic agents--clinical perspectives |
| Q42171251 | New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals |
| Q36186494 | New sources of pancreatic beta-cells |
| Q42078124 | New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins |
| Q37115734 | New therapies for diabetes |
| Q35153309 | New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies |
| Q37992259 | Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide |
| Q51453587 | Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects. |
| Q37375539 | Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment |
| Q39881169 | Noncanonical activation of Akt/protein kinase B in {beta}-cells by the incretin hormone glucose-dependent insulinotropic polypeptide. |
| Q35612166 | Nonpeptidic glucagon-like peptide 1 receptor agonists: a magic bullet for diabetes? |
| Q33679277 | Novel GLP-1 Analog Supaglutide Reduces HFD-Induced Obesity Associated with Increased Ucp-1 in White Adipose Tissue in Mice |
| Q37960149 | Novel GLP-1 receptor agonists for diabetes |
| Q36812821 | Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin |
| Q38089327 | Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013. |
| Q28564632 | Nutrient-driven incretin secretion into intestinal lymph is different between diabetic Goto-Kakizaki rats and Wistar rats |
| Q37852801 | Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential |
| Q38035293 | Obesity and appetite control |
| Q26828559 | Obesity pharmacotherapy: current perspectives and future directions |
| Q33607971 | Obesity treatment: novel peripheral targets |
| Q42554780 | Obesity, a health burden of a global nature |
| Q38080812 | Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the The Obesity Society and The American Society of Hypertension |
| Q38071133 | Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension |
| Q51320034 | Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. |
| Q28287325 | Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial |
| Q40147433 | Once-daily liraglutide (1.2 mg) compared with twice-daily exenatide (10 μg) in the treatment of type 2 diabetes patients: An indirect treatment comparison meta-analysis |
| Q42671884 | Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial |
| Q24656644 | One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial |
| Q30377441 | Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes |
| Q35906506 | Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists |
| Q33664745 | Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action |
| Q90625078 | Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis |
| Q41184651 | Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes |
| Q37260330 | Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. |
| Q91935583 | Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials |
| Q26853311 | Parkinson's disease, insulin resistance and novel agents of neuroprotection |
| Q92044310 | Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies |
| Q35126645 | Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes |
| Q37666711 | Pediatric Dosing and Body Size in Biotherapeutics |
| Q60303096 | Penetration of new antidiabetic medications in East Asian countries and the United States: A cross-national comparative study |
| Q28504803 | Perinatal survivin is essential for the establishment of pancreatic beta cell mass in mice |
| Q37142047 | Pharmacogenetics: potential role in the treatment of diabetes and obesity |
| Q51249870 | Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes. |
| Q49971015 | Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus |
| Q53186529 | Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers. |
| Q38497043 | Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing |
| Q46220335 | Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus |
| Q38388602 | Pharmacologic treatment of type 2 diabetes: injectable medications |
| Q38148574 | Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus |
| Q30249371 | Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus |
| Q36891391 | Pharmacotherapeutic options for overweight adolescents |
| Q80985125 | Pharmacotherapy for obesity |
| Q37581447 | Pharmacotherapy in pediatric obesity: current agents and future directions |
| Q37594792 | Pharmacotherapy of hyperglycemia |
| Q38113095 | Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach |
| Q35968092 | Pleiotropic effects of incretins |
| Q40846502 | Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients |
| Q38789584 | Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration |
| Q37639905 | Population pharmacokinetics of exenatide |
| Q43172648 | Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide |
| Q37364896 | Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing |
| Q38286444 | Potential side effects to GLP-1 agonists: understanding their safety and tolerability |
| Q36391466 | Potential use of exenatide for the treatment of obesity |
| Q33521451 | Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists |
| Q64071214 | Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity |
| Q35909303 | Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes |
| Q34572487 | Present and future: pharmacologic treatment of obesity |
| Q37804597 | Preservation of Beta-Cell Function in Type 2 Diabetes |
| Q36740436 | Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventions |
| Q34452524 | Proglucagon-derived peptides: mechanisms of action and therapeutic potential |
| Q34734056 | Prophylactic use of anti‐emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open‐label, parallel‐group, single‐dose study in healthy subjects |
| Q47630248 | Proportional Feedback Control of Energy Intake During Obesity Pharmacotherapy. |
| Q36756501 | Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis |
| Q34270377 | Quantifying energy intake changes during obesity pharmacotherapy |
| Q36693199 | Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus |
| Q38026956 | Recent advances in incretin-based therapies |
| Q37857695 | Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes |
| Q60707245 | Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2 |
| Q38109836 | Reducing the risk of obesity: defining the role of weight loss drugs |
| Q24658031 | Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders |
| Q37439364 | Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications |
| Q36503839 | Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease |
| Q37884618 | Review of approved pioglitazone combinations for type 2 diabetes |
| Q38016390 | Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus |
| Q92544129 | Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta-analysis |
| Q38235219 | Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials |
| Q33635830 | Role and development of GLP-1 receptor agonists in the management of diabetes. |
| Q35766237 | Role of gastrointestinal hormones in feeding behavior and obesity treatment |
| Q30248510 | Role of glucagon-like peptide 1 receptor agonists in management of obesity |
| Q31066859 | Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program |
| Q34581781 | Safety and adverse effects associated with GLP-1 analogues |
| Q38270204 | Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes |
| Q41831179 | Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks |
| Q35780935 | Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials |
| Q39553746 | Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus |
| Q46507989 | Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*. |
| Q58588917 | Second steps in managing type 2 diabetes |
| Q35496591 | Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis |
| Q34133324 | Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide |
| Q36807640 | Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice |
| Q36047167 | Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets |
| Q53640778 | Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study. |
| Q35620114 | Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes |
| Q44366883 | Sir David Cuthbertson Medal Lecture. Bariatric surgery as a model to study appetite control |
| Q34919698 | Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity |
| Q35612392 | Small-molecule agonists for the glucagon-like peptide 1 receptor |
| Q37412792 | Standards of care for type 2 diabetes in China. |
| Q38946922 | Stimulation of GLP-1 secretion downstream of the ligand-gated ion channel TRPA1. |
| Q40718402 | Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents |
| Q50179577 | Synthesis of evidence for reimbursement decisions: a Bayesian reanalysis |
| Q30401145 | Tackling obesity: new therapeutic agents for assisted weight loss. |
| Q37270524 | Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors |
| Q37091579 | Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins |
| Q38866310 | Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146. |
| Q26738730 | Targeting the gastrointestinal tract to treat type 2 diabetes |
| Q38033552 | The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus |
| Q92823411 | The Effect of Diabetes-Specific Enteral Nutrition Formula on Cardiometabolic Parameters in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials |
| Q35677315 | The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis |
| Q26765609 | The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity |
| Q37811420 | The Role of GLP-1 in Neuronal Activity and Neurodegeneration |
| Q88550258 | The Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Type 2 Diabetes |
| Q39140294 | The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy |
| Q28078225 | The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review |
| Q38982510 | The anorexic effect of Ex4/Fc through GLP-1 receptor activation in high-fat diet fed mice |
| Q36536251 | The burden of type 2 diabetes: strategies to prevent or delay onset |
| Q38134902 | The cardiovascular safety of incretin-based therapies: a review of the evidence |
| Q37992253 | The design of the liraglutide clinical trial programme |
| Q41883921 | The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study |
| Q37980019 | The effect of glucagon-like peptide 1 on cardiovascular risk |
| Q37734567 | The effects of GLP-1 analogues on pre-diabetes of the children |
| Q37954675 | The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review |
| Q37226372 | The effects of pharmacologic agents for type 2 diabetes mellitus on body weight |
| Q30365939 | The entero-insular axis: implications for human metabolism. |
| Q36428803 | The evidence for achieving glycemic control with incretin mimetics |
| Q33866808 | The evolving place of incretin-based therapies in type 2 diabetes |
| Q42054096 | The evolving world of GLP-1 agonist therapies for type 2 diabetes |
| Q38174279 | The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems |
| Q36277582 | The fetal origins of the metabolic syndrome: can we intervene? |
| Q21296779 | The gut hormones in appetite regulation |
| Q35535513 | The gut sensor as regulator of body weight |
| Q33888236 | The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus |
| Q33776092 | The incretin system and cardiometabolic disease |
| Q37813582 | The incretin system in the management of type 2 diabetes mellitus |
| Q28273497 | The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes |
| Q39677369 | The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4. |
| Q34795703 | The non-peptide GLP-1 receptor agonist WB4-24 blocks inflammatory nociception by stimulating β-endorphin release from spinal microglia |
| Q34578590 | The obesity pipeline: current strategies in the development of anti-obesity drugs |
| Q36904452 | The pathophysiology of cardiovascular disease in diabetes mellitus and the future of therapy |
| Q40284076 | The peptide agonist-binding site of the glucagon-like peptide-1 (GLP-1) receptor based on site-directed mutagenesis and knowledge-based modelling |
| Q51365002 | The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. |
| Q53242373 | The physiology of incretin hormones and the basis for DPP-4 inhibitors. |
| Q38088195 | The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists |
| Q37030680 | The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis |
| Q38101677 | The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications |
| Q35251016 | The role of gut hormones in glucose homeostasis |
| Q35760288 | The role of incretin therapy at different stages of diabetes |
| Q46161355 | The role of incretins in cardiovascular control |
| Q34901533 | The role of incretins in glucose homeostasis and diabetes treatment |
| Q42130324 | The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide |
| Q37864256 | The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review |
| Q81630853 | The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects |
| Q34750027 | Therapeutic Approaches for Preserving or Restoring Pancreatic β-Cell Function and Mass. |
| Q37221780 | Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies |
| Q37218121 | Therapeutic management of posttransplant diabetes mellitus |
| Q37682561 | Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes |
| Q34133889 | Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors |
| Q47410483 | Thioamide Substitution Selectively Modulates Proteolysis and Receptor Activity of Therapeutic Peptide Hormones. |
| Q42675447 | To be or not to be--an incretin or enterogastrone? |
| Q34299654 | Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes |
| Q26995176 | Treating the elderly diabetic patient: special considerations |
| Q37609829 | Treating type 2 diabetes: incretin mimetics and enhancers |
| Q37804398 | Treatment of diabetes with glucagon-like peptide-1 gene therapy |
| Q36755470 | Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals |
| Q26783350 | Treatment of prediabetes |
| Q36833164 | Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries |
| Q38634679 | Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review |
| Q46519581 | Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin |
| Q37235875 | Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-b |
| Q37774541 | Type 2 diabetes and obesity in adults |
| Q34620430 | Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies |
| Q42927083 | Understanding GLP-1 Analogs and Enhancing Patient Success |
| Q37161925 | Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents |
| Q36593147 | Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide |
| Q38006504 | Update on incretin hormones |
| Q28073342 | Update on the treatment of type 2 diabetes mellitus |
| Q50560029 | Use of exenatide and liraglutide in Denmark: a drug utilization study. |
| Q41867211 | Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE. |
| Q37910976 | Using albumin to improve the therapeutic properties of diabetes treatments |
| Q80633837 | Utilities and disutilities for type 2 diabetes treatment-related attributes |
| Q37890781 | Utilizing current diagnostic criteria and treatment algorithms for managing type 2 diabetes mellitus |
| Q36269671 | Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches |
| Q34159414 | Weight Considerations in Pharmacotherapy for Type 2 Diabetes |
| Q37801634 | Weight Management in Type 2 Diabetes Mellitus |
| Q46598580 | Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs. |
| Q44245989 | Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. |
| Q34068749 | Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience |
| Q38241464 | What are the pharmacotherapy options for treating prediabetes? |
| Q79319361 | What to inject when oral agents fail? |
| Q84219888 | [Incretins: do they exert cardiovascular effects?] |
| Q80204033 | [New approaches in obesity treatment: the gastrointestinal tract as an endocrine organ] |
| Q83656427 | [Safety and tolerability of oral antidiabetes drugs in the treatment of type 2 diabetes mellitus] |
| Q36947018 | beta-cell function and anti-diabetic pharmacotherapy |
| Q42535316 | β-cell preservation and regeneration for diabetes treatment: where are we now? |